Olmesartan Alone or in Combination With Hydrochlorothiazide in Subjects With Mild to Moderate Essential Hypertension

Pfizer410 enrolled

Overview

Efficacy, tolerability and safety of olmesartan alone or in combination with hydrochlorothiazide in the treatment of mild to moderate essential hypertension

Study Type

INTERVENTIONAL

Allocation

NON_RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

410

Conditions

Essential Hypertension

Interventions

olmesartan alone or in combination with hydrochlorothiazideDRUG

Eligibility

Sex: ALLMin age: 18 YearsMax age: 65 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Subject has mild to moderate hypertension Exclusion Criteria: * History of secondary hypertension

Locations (32)

Outcomes

Primary Outcomes

Efficacy of olmesartan alone or in combination with hydrochlorothiazide in the treatment of mild to moderate essential hypertension

Secondary Outcomes

Safety and tolerability of olmesartan alone or in combination with hydrochlorothiazide in the treatment of mild to moderate essential hypertension

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.

Pfizer Investigational Site

Medellín, Antioquia, Colombia

Pfizer Investigational Site

Barranquilla, Atlántico, Colombia

Pfizer Investigational Site

Cartagena, Atlántico, Colombia

Pfizer Investigational Site

Bogota, Cundinamarca, Colombia

Pfizer Investigational Site

Cali, Valle del Cauca Department, Colombia

Pfizer Investigational Site

Escobedo, Guayas, Ecuador

Pfizer Investigational Site

Quito, Pichincha, Ecuador

Pfizer Investigational Site

NT, Hong Kong

Pfizer Investigational Site

Shatin, NT, Hong Kong

Pfizer Investigational Site

Jakarta, Indonesia

...and 22 more locations